Cellemics (셀레믹스)
KOSDAQ · KRX: 331920
Cellemics is a South Korean biotechnology company that specializes in cell therapy and regenerative medicine, focusing on the development of therapeutic solutions using cellular technologies. The company is listed on the KOSDAQ market, South Korea's secondary exchange for smaller and growth-oriented companies. Cellemics operates within the broader biotech sector, contributing to the advancement of cell-based treatment options for various medical applications.
Filing timeline
mediumspotted 10:02 KST
Cellemics (KRX: 331920)- Park Jong-gap (박종갑), co-representative director (공동대표이사) and registered officer (등기임원), holds 2,259,634 shares
- Shareholding represents 22.74% of outstanding shares, qualifying as 10%-plus major shareholder (10%이상주주)
- Filing date 18 March 2026; report submitted under insider holding disclosure rules (임원ㆍ주요주주특정증권등소유상황보고서)
View original DART filing ↗mediumspotted 11:52 KST
Cellemics (KRX: 331920)- Park Jong-gap (박종갑), co-representative director (공동대표이사), holds 2,259,634 shares representing 22.74% of outstanding shares
- Holding classified as both executive officer (등기임원) and major shareholder (10%이상주주)
- Report filed 18 March 2026 (rcept_no 20260318000994) under insider disclosure rules
View original DART filing ↗mediumspotted 11:06 KST
Cellemics (KRX: 331920)- Park Jong-gab (박종갑) reports ownership of 2,259,634 shares, representing 22.74% of outstanding shares
- Park holds the position of co-representative director (공동대표이사) and is classified as a major shareholder (10%이상주주)
- Filing submitted 18 March 2026 under insider disclosure regime for officers and major shareholders (임원ㆍ주요주주특정증권등소유상황보고서)
View original DART filing ↗AI-generated summaries of public DART filings. May contain errors — always verify against the original (linked). Not investment advice.